Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer

被引:6
|
作者
Ferreira, M. R. [1 ,2 ,4 ,5 ]
Thomas, K. [2 ]
Truelove, L. [1 ,2 ]
Khan, A. [1 ,2 ]
Parker, C. [1 ,2 ]
Dearnaley, D. P. [1 ,2 ]
Gulliford, S. [1 ,3 ]
机构
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Kings Coll London, London, England
关键词
Dose-volume constraints; dosimetry; IMRT; pelvic lymph nodes; prostate cancer; gastrointestinal side-effects; SMALL-BOWEL TOXICITY; RADIATION-THERAPY; RECTAL TOXICITY; NORMAL TISSUE; VOLUME; 3D-CRT; PREDICTORS; IMRT;
D O I
10.1016/j.clon.2019.02.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal toxicity. Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypofractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving specified doses and clinician- and patient-reported toxicity outcomes were investigated independently. A metric, delta median (delta M), was defined as the difference in the medians of a volume between groups with and without toxicity at a specified dose and was used to test for statistically significant differences. Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical significance was limited after correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2+ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above the treatment planning constraint. Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using CFRT or HFRT. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd.
引用
收藏
页码:374 / 384
页数:11
相关论文
共 50 条
  • [21] Phase II Trial of GM-CSF in Advanced Prostate Cancer
    Robert Dreicer
    William A. See
    Eric A. Klein
    Investigational New Drugs, 2001, 19 : 261 - 265
  • [22] Phase II trial of GM-CSF in advanced prostate cancer
    Dreicer, R
    See, WA
    Klein, EA
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (03) : 261 - 265
  • [23] Survival Outcomes of Radical Prostatectomy plus Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis
    Chen, Junru
    Ni, Yuchao
    Sun, Guangxi
    Zhu, Sha
    Zhao, Jinge
    Wang, Zhipeng
    Zhang, Haoran
    Zhu, Xudong
    Zhang, Xingming
    Dai, Jindong
    Shen, Pengfei
    Zeng, Hao
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
    Kawakami, S.
    Tsumura, H.
    Satoh, T.
    Tabata, K.
    Sekiguchi, A.
    Kainuma, T.
    Nakano, M.
    Iwamura, M.
    Ishiyama, H.
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [25] Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial
    Tey, Jeremy
    Zheng, Huili
    Soon, Yu Y.
    Leong, Cheng N.
    Koh, Wee Y.
    Lim, Keith
    So, Jimmy B. Y.
    Shabbir, Asim
    Tham, Ivan W. K.
    Lu, Jiade
    CANCER MEDICINE, 2019, 8 (04): : 1447 - 1458
  • [26] Toxicity of Pelvic Lymph Node Irradiation with IMRT for High-Risk Prostate Cancer In Regard to Parry et al
    Murthy, Vedang
    Srinivasan, Shashank
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (03): : 918 - 918
  • [27] Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
    B. H. E. Jansen
    Y. J. L. Bodar
    G. J. C. Zwezerijnen
    D. Meijer
    J. P. van der Voorn
    J. A. Nieuwenhuijzen
    M. Wondergem
    T. A. Roeleveld
    R. Boellaard
    O. S. Hoekstra
    R. J. A. van Moorselaar
    D. E. Oprea-Lager
    A. N. Vis
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 509 - 520
  • [28] Is there an indication for radiotherapy of the pelvic lymphatics in patients with locally advanced prostate cancer (T2b-T4 N0) without clinical evidence of lymph node metastases or in patients with locoregional advanced prostate cancer (Tx N+) with lymph node metastases?
    Wiegel, T
    Hinkelbein, W
    STRAHLENTHERAPIE UND ONKOLOGIE, 1998, 174 (05) : 231 - 236
  • [29] STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: INTERIM RESULTS OF A PROSPECTIVE PHASE II CLINICAL TRIAL
    King, Christopher R.
    Brooks, James D.
    Gill, Harcharan
    Pawlicki, Todd
    Cotrutz, Cristian
    Presti, Joseph C., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (04): : 1043 - 1048
  • [30] Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer An investigation of 117 pelvic lymph nodes
    Cozzi, Salvatore
    Botti, Andrea
    Timon, Giorgia
    Blandino, Gladys
    Najafi, Masoumeh
    Manicone, Moana
    Bardoscia, Lilia
    Ruggieri, Maria Paola
    Ciammella, Patrizia
    Iotti, Cinzia
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (08) : 700 - 709